Welireg looks headed to regulators in second-line and adjuvant kidney cancer.
ApexOnco Front Page
Recent articles
27 February 2026
The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
18 February 2026
Gilead opting against IDE397 is still good news for Ideaya.
17 February 2026
Progression-free and overall survival data from Companion-002 are due this quarter.
16 February 2026
JSKN027 will become the first ADC with this mechanism to enter human trials.
16 February 2026
Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
13 February 2026
A binary Xpovio catalyst is set for March.